GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (FRA:8NE) » Definitions » Cyclically Adjusted Price-to-FCF

Lisata Therapeutics (FRA:8NE) Cyclically Adjusted Price-to-FCF : (As of Jun. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lisata Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lisata Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Lisata Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Cyclically Adjusted Price-to-FCF Chart

Lisata Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lisata Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lisata Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Lisata Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lisata Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Lisata Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Lisata Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Lisata Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.779/131.7762*131.7762
=-0.779

Current CPI (Mar. 2024) = 131.7762.

Lisata Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -43.231 100.560 -56.651
201409 -46.333 100.428 -60.796
201412 -39.317 99.070 -52.297
201503 -53.693 99.621 -71.024
201506 -27.135 100.684 -35.515
201509 -22.940 100.392 -30.112
201512 -22.803 99.792 -30.111
201603 -21.272 100.470 -27.900
201606 -14.840 101.688 -19.231
201609 -12.071 101.861 -15.616
201612 -5.912 101.863 -7.648
201703 -16.989 102.862 -21.765
201706 -0.770 103.349 -0.982
201709 -8.794 104.136 -11.128
201712 -5.339 104.011 -6.764
201803 -8.030 105.290 -10.050
201806 -7.887 106.317 -9.776
201809 -6.437 106.507 -7.964
201812 -4.070 105.998 -5.060
201903 -7.268 107.251 -8.930
201906 -6.026 108.070 -7.348
201909 -5.831 108.329 -7.093
201912 -5.441 108.420 -6.613
202003 -5.424 108.902 -6.563
202006 4.547 108.767 5.509
202009 -2.409 109.815 -2.891
202012 -3.540 109.897 -4.245
202103 -2.386 111.754 -2.813
202106 -0.968 114.631 -1.113
202109 -1.078 115.734 -1.227
202112 -1.021 117.630 -1.144
202203 -1.269 121.301 -1.379
202206 -1.187 125.017 -1.251
202209 -0.851 125.227 -0.896
202212 -0.773 125.222 -0.813
202303 -0.958 127.348 -0.991
202306 -0.481 128.729 -0.492
202309 -0.412 129.860 -0.418
202312 -0.458 129.419 -0.466
202403 -0.779 131.776 -0.779

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lisata Therapeutics  (FRA:8NE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Lisata Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lisata Therapeutics (FRA:8NE) Business Description

Industry
Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Lisata Therapeutics (FRA:8NE) Headlines

No Headlines